Program
netarsudil
Also written as “AR-13324 Ophthalmic Solution 0.02%”, “Netarsudil Ophthalmic Solution 0.02%” and “Netarsudil ophthalmic solution 0.02%”.
Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Fuchs' Endothelial Dystrophy · Corneal Edema, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alcon | 180 open or running | phase 4since Jan 10, 2019 | Feb 5, 2012 | none ahead |
| Price Vision Group | 20 open or running | phase 3since May 30, 2019 | May 30, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Feb 5, 2012.
- Mar 12, 2015Phase 1 study in Healthy SubjectsAlcon · NCT02406287 · 10 enrolled · United States
- Sep 16, 2015Phase 3 study in Glaucoma, Open-AngleAlcon · NCT02558374 · 708 enrolled · United States
- Aug 15, 2016Phase 2 study in Ocular HypertensionAlcon · NCT02874846 · 12 enrolled · United States
- Jul 12, 2017Phase 2 study in Glaucoma, Open-AngleAlcon · NCT03233308 · 20 enrolled · United States
- Aug 29, 2017Phase 3 study in Glaucoma, Open-AngleAlcon · NCT03284853 · 436 enrolled · Austria, Belgium, Czechia and more
- Oct 13, 2017Phase 2 study in Glaucoma, Open-AngleAlcon · NCT03310580 · 42 enrolled · United States
- Jan 10, 2019Phase 4 study in Glaucoma, Open-AngleAlcon · NCT03808688 · 261 enrolled · United States
- Feb 15, 2019Phase 2 study in Glaucoma, Open-AngleAlcon · NCT03844945 · 215 enrolled · Japan
- May 30, 2019Price Vision Group's first study: phase 3 study in Fuchs' Endothelial DystrophyNew to Price Vision GroupPrice Vision Group · NCT03971357 · 19 enrolled · United States
- Aug 7, 2019Phase 3 study in Fuchs' Endothelial DystrophyPrice Vision Group · NCT04051463 · 29 enrolled · United States
- Jul 31, 2020Phase 2 study in Corneal EdemaAlcon · NCT04498169 · 40 enrolled · United States
- Oct 26, 2020Phase 3 study in Glaucoma, Open-AngleAlcon · NCT04620135 · 245 enrolled · Japan
- Mar 7, 2022Phase 4 study in GlaucomaAlcon · NCT05283395 · 136 enrolled · United States
- Jul 17, 2025Phase 3 study in Ocular HypertensionAlcon · NCT07082816 · 489 enrolled · United States
TargetBeta
“Rho-associated protein kinase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| belumosudilrule | Sanofi | phase 4 | 26 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07082816Ocular Hypertension · United States | 3 | Completed | Alcon | Apr 6, 2026 | 489 |
| NCT05283395Glaucoma · United States | 4 | Completed | Alcon | Mar 22, 2023 | 136 |
| NCT04620135Glaucoma, Open-Angle · Japan | 3 | Completed | Alcon | Jul 9, 2021 | 245 |
| NCT04498169Corneal Edema · United States | 2 | Completed | Alcon | Aug 11, 2021 | 40 |
| NCT04051463Fuchs' Endothelial Dystrophy · United States | 3 | Completed | Price Vision Group | Jul 1, 2020 | 29 |
| NCT03971357Fuchs' Endothelial Dystrophy · United States | 3 | Terminated | Price Vision Group | Aug 26, 2021 | 19 |
| NCT03844945Glaucoma, Open-Angle · Japan | 2 | Completed | Alcon | Sep 19, 2019 | 215 |
| NCT03808688Glaucoma, Open-Angle · United States | 4 | Completed | Alcon | Jul 26, 2019 | 261 |
| NCT03310580Glaucoma, Open-Angle · United States | 2 | Completed | Alcon | Oct 25, 2018 | 42 |
| NCT03284853Glaucoma, Open-Angle · Austria, Belgium, Czechia and more | 3 | Completed | Alcon | Nov 6, 2020 | 436 |
| NCT03233308Glaucoma, Open-Angle · United States | 2 | Completed | Alcon | Apr 19, 2018 | 20 |
| NCT02874846Ocular Hypertension · United States | 2 | Completed | Alcon | Sep 2016 | 12 |
| NCT02558374Glaucoma, Open-Angle · United States | 3 | Completed | Alcon | Dec 2016 | 708 |
| NCT02406287Healthy Subjects · United States | 1 | Completed | Alcon | Apr 2016 | 10 |
| NCT02246764Ocular Hypertension · United States | 3 | Completed | Alcon | Dec 2016 | 93 |
| NCT02207621Ocular Hypertension · United States | 3 | Completed | Alcon | Mar 2016 | 756 |
| NCT02207491Ocular Hypertension · United States | 3 | Completed | Alcon | Mar 2015 | 411 |
| NCT01997879Healthy · United States | 1 | Completed | Alcon | Nov 2013 | 18 |
| NCT01731002Ocular Hypertension · United States | 2 | Completed | Alcon | May 2013 | 224 |
| NCT01528787Ocular Hypertension · United States | 2 | Completed | Alcon | Jul 2012 | 85 |
How it is read
Names in the registry
- “AR-13324 Ophthalmic Solution 0.02%”, 7 entries
- “Netarsudil Ophthalmic Solution 0.02%”, 3 entries
- “Netarsudil ophthalmic solution 0.02%”, 2 entries
- “Netarsudil Ophthalmic”, 2 entries
- “AR-13324 Ophthalmic Solution 0.04%”, 2 entries
Conditions, from the studies’ own filings
- Glaucoma, Open-Angle, 13 studies
- Glaucoma, 2 studies
- Fuchs' Endothelial Dystrophy, 2 studies
- Corneal Edema, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.